Loading...

Theravance Biopharma

DB:0TB
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0TB
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Theravance Biopharma has significant price volatility in the past 3 months.
0TB Share Price and Events
7 Day Returns
-11.3%
DB:0TB
-3.1%
DE Pharmaceuticals
-3.2%
DE Market
1 Year Returns
-17.6%
DB:0TB
-30.8%
DE Pharmaceuticals
-11.6%
DE Market
0TB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Theravance Biopharma (0TB) -11.3% -22% -26.9% -17.6% -18.1% -
DE Pharmaceuticals -3.1% -8.8% -12.3% -30.8% -22% 6.1%
DE Market -3.2% -5.1% 0.3% -11.6% 5.3% 5.9%
1 Year Return vs Industry and Market
  • 0TB outperformed the Pharmaceuticals industry which returned -30.8% over the past year.
  • 0TB underperformed the Market in Germany which returned -11.6% over the past year.
Price Volatility
0TB
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Theravance Biopharma's competitors could be found in our database.

Value

 Is Theravance Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Theravance Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Theravance Biopharma.

DB:0TB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0TB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.693 (1 + (1- 21%) (49.92%))
0.978
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.98
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.978 * 5.96%)
6.06%

Discounted Cash Flow Calculation for DB:0TB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Theravance Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0TB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.06%)
2019 -215.00 Analyst x1 -202.72
2020 -187.00 Analyst x1 -166.26
2021 -122.00 Analyst x1 -102.27
2022 -11.00 Analyst x1 -8.69
2023 197.00 Analyst x1 146.83
2024 331.98 Est @ 68.52% 233.30
2025 491.42 Est @ 48.03% 325.63
2026 656.98 Est @ 33.69% 410.48
2027 812.36 Est @ 23.65% 478.58
2028 947.41 Est @ 16.62% 526.27
Present value of next 10 years cash flows $1,641.12
DB:0TB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $947.41 × (1 + 0.23%) ÷ (6.06% – 0.23%)
$16,294.62
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $16,294.62 ÷ (1 + 6.06%)10
$9,051.33
DB:0TB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,641.12 + $9,051.33
$10,692.45
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,692.45 / 56.14
$190.47
DB:0TB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0TB represents 0.89164x of NasdaqGM:TBPH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89164x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 190.47 x 0.89164
€169.83
Value per share (EUR) From above. €169.83
Current discount Discount to share price of €16.21
= -1 x (€16.21 - €169.83) / €169.83
90.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Theravance Biopharma is available for.
Intrinsic value
>50%
Share price is €16.21 vs Future cash flow value of €169.83
Current Discount Checks
For Theravance Biopharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Theravance Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Theravance Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Theravance Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Theravance Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0TB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.10
NasdaqGM:TBPH Share Price ** NasdaqGM (2019-05-24) in USD $18.18
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.65x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.22x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Theravance Biopharma.

DB:0TB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TBPH Share Price ÷ EPS (both in USD)

= 18.18 ÷ -4.10

-4.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Theravance Biopharma is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Theravance Biopharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Theravance Biopharma's expected growth come at a high price?
Raw Data
DB:0TB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
40.5%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.85x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Theravance Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Theravance Biopharma's assets?
Raw Data
DB:0TB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-2.02
NasdaqGM:TBPH Share Price * NasdaqGM (2019-05-24) in USD $18.18
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.24x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
DB:0TB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TBPH Share Price ÷ Book Value per Share (both in USD)

= 18.18 ÷ -2.02

-9.01x

* Primary Listing of Theravance Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Theravance Biopharma has negative assets, we can't compare the value of its assets to the DE Pharmaceuticals industry average.
X
Value checks
We assess Theravance Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Theravance Biopharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Theravance Biopharma expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Theravance Biopharma expected to grow at an attractive rate?
  • Theravance Biopharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Theravance Biopharma's earnings growth is expected to exceed the Germany market average.
  • Theravance Biopharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0TB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0TB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 40.5%
DB:0TB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 39.5%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0TB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0TB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 298 166 136 4
2022-12-31 204 -21 -81 4
2021-12-31 116 -149 -198 4
2020-12-31 108 -185 -254 6
2019-12-31 51 -267 -271 6
DB:0TB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 57 -244 -223
2018-12-31 60 -113 -216
2018-09-30 49 -105 -252
2018-06-30 41 -118 -260
2018-03-31 21 -101 -285
2017-12-31 15 -201 -285
2017-09-30 17 -185 -266
2017-06-30 31 -135 -233
2017-03-31 33 -123 -214
2016-12-31 49 -99 -191
2016-09-30 47 -105 -168
2016-06-30 38 -124 -182

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Theravance Biopharma's earnings are expected to grow significantly at over 20% yearly.
  • Theravance Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0TB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Theravance Biopharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0TB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.25 2.45 -0.69 3.00
2022-12-31 -1.36 -0.11 -2.88 3.00
2021-12-31 -3.44 -2.76 -4.32 3.00
2020-12-31 -3.60 -0.94 -5.76 5.00
2019-12-31 -4.71 -4.03 -5.20 5.00
DB:0TB Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.10
2018-12-31 -3.99
2018-09-30 -4.71
2018-06-30 -4.89
2018-03-31 -5.40
2017-12-31 -5.45
2017-09-30 -5.16
2017-06-30 -4.66
2017-03-31 -4.45
2016-12-31 -4.26
2016-09-30 -4.06
2016-06-30 -4.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Theravance Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Theravance Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Theravance Biopharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Theravance Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Theravance Biopharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Theravance Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Theravance Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Theravance Biopharma's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Theravance Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Theravance Biopharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0TB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 57.39 -223.02 97.54
2018-12-31 60.37 -215.52 97.06
2018-09-30 49.15 -252.26 98.52
2018-06-30 40.59 -259.70 100.18
2018-03-31 20.62 -285.17 99.51
2017-12-31 15.39 -285.41 95.59
2017-09-30 16.56 -265.82 86.44
2017-06-30 31.36 -232.90 85.78
2017-03-31 33.33 -213.84 81.70
2016-12-31 48.65 -190.67 84.51
2016-09-30 46.85 -168.16 88.21
2016-06-30 38.47 -181.52 90.77
2016-03-31 40.14 -181.90 92.05
2015-12-31 42.13 -182.22 90.20
2015-09-30 39.67 -201.70 87.91
2015-06-30 35.30 -208.88 82.77
2015-03-31 31.14 -219.49 74.34
2014-12-31 11.69 -237.04 71.65
2014-09-30 10.43 -216.81 61.66
2014-06-30 4.12 -203.39 52.76
2014-03-31 1.15 -184.13 48.20
2013-12-31 0.23 -156.28 35.93
2013-09-30 4.53 -141.39 30.61 -73.61
2013-06-30 4.50 -132.90 28.31 -47.52
2013-03-31 4.50 -128.78 26.03 -18.96
2012-12-31 130.15 -9.58 25.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Theravance Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Theravance Biopharma has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Theravance Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Theravance Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Theravance Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Theravance Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Theravance Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Theravance Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Theravance Biopharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Theravance Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Theravance Biopharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Theravance Biopharma Company Filings, last reported 1 month ago.

DB:0TB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -113.25 511.70 445.76
2018-12-31 -51.59 454.35 505.28
2018-09-30 -13.45 224.55 300.41
2018-06-30 34.39 224.28 352.90
2018-03-31 63.41 224.01 418.53
2017-12-31 115.18 223.75 348.57
2017-09-30 184.12 223.48 335.00
2017-06-30 241.13 223.21 361.82
2017-03-31 293.95 222.94 392.77
2016-12-31 350.23 222.68 501.10
2016-09-30 297.87 0.00 230.48
2016-06-30 321.58 0.00 249.68
2016-03-31 238.54 0.00 179.88
2015-12-31 243.07 0.00 172.43
2015-09-30 222.55 0.00 195.97
2015-06-30 257.67 0.00 210.99
2015-03-31 289.12 0.00 236.24
2014-12-31 289.79 0.00 254.61
2014-09-30 339.82 0.00 284.72
2014-06-30 384.76 0.00 349.20
2014-03-31 -17.92 0.00
2013-12-31 -17.04 0.00
2013-09-30 -14.37 0.00
2013-06-30 -12.06 0.00
2013-03-31 -4.38 0.00
2012-12-31 -6.99 0.00
  • Theravance Biopharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Theravance Biopharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Theravance Biopharma has sufficient cash runway for 1.8 years based on current free cash flow.
  • Theravance Biopharma has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 11.3% each year.
X
Financial health checks
We assess Theravance Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Theravance Biopharma has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Theravance Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Theravance Biopharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Theravance Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Theravance Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Theravance Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0TB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0TB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Theravance Biopharma has not reported any payouts.
  • Unable to verify if Theravance Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Theravance Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Theravance Biopharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Theravance Biopharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Theravance Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Theravance Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Theravance Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Theravance Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Winningham
COMPENSATION $2,522,841
AGE 58
TENURE AS CEO 4.9 years
CEO Bio

Mr. Rick E. Winningham has been the Chairman and Chief Executive Officer at Theravance Biopharma, Inc. since its spin-off from Theravance, Inc. since July 2013 and since June 2014 respectively. Mr. Winningham served as the Chief Executive Officer of Innoviva from October 2001 to August 15, 2014. He served as the President of Theravance Inc. since October 2001. From 1997 to 2001, he served as the President of Bristol-Myers Squibb Oncology /Immunology /Oncology Therapeutics Network (OTN) from 1997 to 2001 and as the President of Global Marketing from 2000 to 2001. Along with operating responsibility for U.S. Oncology/Immunology/OTN at Bristol-Myers Squibb (BMS), he had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU /GI /Neuroscience therapeutic areas. During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol®, Paraplatin®, Zerit®, Videx®, Reyataz® and Abilify®. He was the Chairman of California Life Sciences Association from March 2015 to November 2015 and serves as its Director. He was the Chairman of the Board of Directors of California Healthcare Institute from January 2014 to March 2015. Mr. Winningham served as the Chairman of Innoviva from April 2010 to October 30, 2014. He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Company since May 2014 and January 2012 respectively and was a director of Jazz Pharmaceuticals, Inc. from 2010 until the closing of the Azur Merger. He was a Director of California Healthcare Institute since November 2011 until March 2015. He served as Director at OncoMed Pharmaceuticals, Inc. since June 29, 2015 until April 23, 2019 and serves as Director of Theravance Biopharma, Inc. since July 2013. He serves as a Member of Advisory Board at NovaMed Pharmaceuticals Inc. He is a member of the Board of Directors of the Biotechnology Innovation Organization (BIO). He served as a Director of Theravance Inc. from October 2001 to October 30, 2014 and Azur Pharma Public Limited Company. He is a Member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University and holds a seat on the Advisory Council for the Keck Graduate Institute. He is also a Member of Biotechnology Industry Organization’s Board of Directors and serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham holds a BS degree from Southern Illinois University and a Master's of Business Administration from Texas Christian University.

CEO Compensation
  • Rick's compensation has increased whilst company is loss making.
  • Rick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Theravance Biopharma management team in years:

3.2
Average Tenure
58
Average Age
  • The tenure for the Theravance Biopharma management team is about average.
Management Team

Rick Winningham

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
58
TENURE
4.9 yrs

Bradford Shafer

TITLE
Executive VP
COMPENSATION
$1M
AGE
58
TENURE
4.7 yrs

Brett Haumann

TITLE
Senior VP of Clinical Development & Chief Medical Officer
COMPENSATION
$2M
AGE
48
TENURE
4.4 yrs

Jessica Stitt

TITLE
Vice President of Finance and Investor Relations

Vijay Sabesan

TITLE
Senior Vice President of Technical Operations
TENURE
1.8 yrs

Alex Dobbin

TITLE
Head of Investor Relations

Rhonda Farnum

TITLE
Vice President of Sales & Marketing
TENURE
0.8 yrs

Dennis Driver

TITLE
Senior VP of Human Resources
TENURE
3.2 yrs

Frank Pasqualone

TITLE
Senior VP & Chief Commercial Operations Officer
COMPENSATION
$906K
AGE
62
TENURE
3.2 yrs

Sharath Hegde

TITLE
Senior Vice President of Research
COMPENSATION
$2M
AGE
54
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Theravance Biopharma board of directors in years:

5.3
Average Tenure
66.5
Average Age
  • The tenure for the Theravance Biopharma board of directors is about average.
Board of Directors

Rick Winningham

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
58
TENURE
5.8 yrs

Burt Malkiel

TITLE
Director
COMPENSATION
$386K
AGE
85
TENURE
5.6 yrs

Bill Young

TITLE
Lead Independent Director
COMPENSATION
$392K
AGE
73
TENURE
5.1 yrs

Susan Molineaux

TITLE
Director
COMPENSATION
$357K
AGE
64
TENURE
4.1 yrs

Eran Broshy

TITLE
Director
COMPENSATION
$365K
AGE
59
TENURE
4.9 yrs

Bob Gunderson

TITLE
Director
COMPENSATION
$342K
AGE
66
TENURE
5.6 yrs

Dean Mitchell

TITLE
Director
COMPENSATION
$361K
AGE
62
TENURE
4.9 yrs

Peter Ringrose

TITLE
Director
COMPENSATION
$366K
AGE
72
TENURE
5.6 yrs

George Whitesides

TITLE
Director
COMPENSATION
$354K
AGE
79
TENURE
5.6 yrs

Donal O'Connor

TITLE
Director
COMPENSATION
$361K
AGE
67
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • Theravance Biopharma insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. May 19 Sell Donal O'Connor Individual 16. May 19 17. May 19 -4,000 €18.82 €-73,324
07. Mar 19 Sell Sharathchandra Hegde Individual 04. Mar 19 05. Mar 19 -9,033 €22.17 €-197,504
14. Sep 18 Sell Phillip Worboys Individual 12. Sep 18 12. Sep 18 -6,393 €24.49 €-156,547
29. Aug 18 Sell Bradford Shafer Individual 27. Aug 18 27. Aug 18 -7,119 €23.74 €-169,031
16. Aug 18 Sell Reneé Galá Individual 14. Aug 18 15. Aug 18 -43,743 €24.50 €-1,035,043
09. Aug 18 Sell Bradford Shafer Individual 07. Aug 18 08. Aug 18 -31,300 €24.98 €-753,709
08. Jun 18 Sell Bradford Shafer Individual 06. Jun 18 08. Jun 18 -14,040 €20.48 €-286,149
X
Management checks
We assess Theravance Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Theravance Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company’s product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Details
Name: Theravance Biopharma, Inc.
0TB
Exchange: DB
Founded: 2013
$914,562,828
56,137,175
Website: http://www.theravance.com
Address: Theravance Biopharma, Inc.
Ugland House,
South Church Street,
George Town,
KY1-1104,
Cayman Islands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TBPH Common Shares Nasdaq Global Market US USD 16. May 2014
DB 0TB Common Shares Deutsche Boerse AG DE EUR 16. May 2014
Number of employees
Current staff
Staff numbers
363
Theravance Biopharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 22:02
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.